All articles

Press Releases Bg

iOnctura commences randomized Phase II study in metastatic uveal melanoma

Press Releases Bg

iOnctura strengthens leadership with appointments of Chief Business Officer and Board Chair

Data & Publications Bg

Transforming growth factor beta receptor type I (TGF-βRI) kinase inhibitors IOA-359 and IOA-360 stimulate erythropoiesis in MDS

Press Releases Bg

iOnctura reaches new clinical milestones in uveal melanoma

Data & Publications Bg

Pancreatic CAF-derived Autotaxin (ATX) drives autocrine CTGF expression to modulate pro-tumorigenic signaling

Press Coverage Bg

Drug Target Review – Biotech leader champions targeted cancer treatments and diversity

Data & Publications Bg

High levels of autotaxin and lysophosphatidic acid predict poor outcome in treatment of resectable gastric carcinoma

Data & Publications Bg

Roginolisib (IOA-244), a first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3Kδ) in patients with metastatic uveal melanoma

Press Coverage Bg

MedNous – Small company, big theme: How iOnctura is pursuing drug resistance

Press Releases Bg

iOnctura announces expansion of roginolisib clinical trial program to NSCLC

Press Coverage Bg

Endpoints News – iOnctura raises €80M to advance early-stage rare eye cancer treatment

Press Coverage Bg

FirstWord Pharma – With fresh €80M in hand, iOnctura looks to chart new PI3K path

Hero Bg

Looking for media
resources?